Total Artificial Heart
dc.contributor.author | Elsaeiti, Sajedah | |
dc.contributor.author | Hamouda, Yomna | |
dc.contributor.author | Eloriby, Doaa | |
dc.contributor.author | Elmesmari, Shahed | |
dc.date.accessioned | 2021-02-28T11:19:52Z | |
dc.date.available | 2021-02-28T11:19:52Z | |
dc.date.issued | 2021-02-28 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/2788 | |
dc.description | Heart transplantation remains the gold standard treatment for endstage heart failure. The Total Artificial Heart (TAH) is the only Food and Drug Administration (FDA) approved artificial heart used for bridging patients to transplantation. Outcomes in patients who undergo implantation of the TAH at experienced centers have been good and reproducible. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Faculty of Pharmacy | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Total Artificial Heart | en_US |
dc.type | Presentation | en_US |